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Purpose: To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of
glycation, on the development of diabetic cataract in rat.
Methods: Rats were made diabetic with streptozotocin, and based on the level of plasma glucose, they were assigned as
non-diabetic rats (<14 mmol/l plasma glucose) and diabetic rats (>14 mmol/l plasma glucose). Animals in the treated
groups received CA, AG, and ASA as drops to the left eyes starting from the day of streptozotocin injection. Progression
of lens opacification was recorded using the slit lamp at regular time intervals. All the rats were killed after the week 13,
and the levels of advanced glycation end products (AGE), glutathione reductase (GR), catalase (CAT), and glutathione
(GSH) were determined.
Results: Lens opacification progressed in a biphasic manner in the diabetic rats, an initial slow increase during the first
eight weeks of diabetes followed by a steep increase in the next five weeks. Carnosine treatment delayed the progression
of cataracts in diabetic rats, and the delay was statistically significant on the fourth week of diabetes (p<0.05, when
compared with untreated moderately diabetic rats). A decrease in the antioxidant enzymes of CAT and the level of GSH
was found in the lens of the untreated diabetic rats at 13 weeks after injection. Some protection was provided in the treated
eyes. The level of glycation in the untreated diabetic rats was significantly higher than that in the normal rats (p<0.001).
After treatment with CA, AG, and ASA, those diabetic rats had a lower level of glycated lens protein compared to the
untreated diabetic rats (p<0.001).
Conclusions: These results thus suggest that the effect of CA, AG, and ASA is indeed inhibition of the formation of
AGEs. However, the effect of CA, AG, and ASA is overwhelmed by the excessive accumulation of AGEs in the severely
diabetic rats. CA compared with AG and ASA treatment can delay the progression of lens opacification in the diabetic
rats only during the earlier stages. It also protects against the inactivation of enzymes.
Cataract is a leading cause for blindness. Worldwide 17
million people are blind because of cataract formation, and
the problem will grow in parallel with aging of the population
[1,2].  Surgical  treatment  with  phacoemulsification  and
intraocular  lens  implantation  remains  the  only  proven
treatment. This, however, is associated with significant cost
and  is  not  readily  available  especially  in  the  developing
countries where the prevalence of cataract is the highest. The
serious  complications  as  a  result  of  cataract  surgery  are
inevitable and expensive. Thus, risk and cost factors drive the
study of pharmaceutical approaches to the maintenance of
lens  transparency,  and  it  is  therefore  a  highly  desirable
alternative.
Cataracts are aggregates that result from dysfunctional
protein interactions leading to increased lens opacity [1]. The
cause of protein aggregation and hence lens opacity remains
poorly understood. Posttranslational modifications (PTM) of
lens  crystallins,  consequent  to  aging  or  diseases  such  as
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diabetes,  may  result  in  conformational  changes  and
aggregation of these proteins and lead to lens opacification
and  cataract  formation.  Chemical  modifications  of  lens
proteins and enzymes by reactions such as glycation play an
important and pivotal role.
Glycation,  the  non-enzymic  reaction  of  sugars  with
protein, occurs normally but to an increased extent during
aging and diabetic complications [3]. Glycation and other
non-enzymic posttranslational modifications of proteins have
been implicated in the complications of diabetes and other
conditions. It can lead to protein cross-linking and further
aggregates,  which  contribute  to  the  pathogenesis  of
conformational diseases including cataract and complications
of diabetes [3]. Glycation leads to protein cross-linking, which
may act as a nucleation site that causes further aggregation.
Glycation and especially advanced glycation producing cross-
linking cause a decrease in chaperone function of α-crystallin
and the inactivation of enzymes [4-7]. Advanced glycation
end products (AGEs) induced by hyperglycemia contribute to
cataract formation. Medical treatment of cataract through the
prevention of these modifications and its consequences is
therefore a highly desired alternative [8,9].
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2282Carnosine (CA), a naturally occurring dipeptide (beta-
alanyl-L-histidine),  is  found  predominantly  in  long-lived
tissues including the brain, innervated muscle, and the lens in
surprisingly high amounts (up to 20 mM in human muscle)
[10]. It appears to possess antiglycating, antioxidant, and free-
radical  scavenging  activity  and  could  be  useful  in  any
degenerative condition where posttranslational modification
plays a role [11-13]. It was discovered by the Russian scholars,
Gulewitsch and Amiradzibi, in 1900. Other Russian scholars,
namely Severin and Boldyrev [14], made great contributions
to research on the biological effects and medical application
of CA. CA can inhibit cross-linking of proteins [10,12,15] and
protects  against  the  inactivation  of  enzymes  induced  by
glycation, oxidation, and a steroid [16-18]. In addition, CA
can modulate the reactivity of the glycated protein toward α-
crystallin [19], directly reacts with sugars [10], and inhibits
modifications and the decreased molecular chaperone activity
of lens α-crystallin induced by glycation [7]. Protein cross-
linking is a consequence of glycation that induces formation
of carbonyl (CO) groups. CA can react with protein CO groups
and thereby modulate their deleterious interaction with other
polypeptides [19]. The potential biological and therapeutic
significance of CA against human age-related cataract and
canine cataract has been reported, indicating that CA has the
potential of being a drug to prevent and treat cataract [14,
20-22].
Aminoguanidine  (AG)  as  an  antiglycation  drug  can
inhibit a variety of diabetic complications by trapping the
reactive carbonyls and preventing the formation of AGEs
[23-26]. Diabetics have increased glucosamine levels. It is
possible that the glycation of the lens structural proteins by
glucosamine induces conformational changes in the lens that
contribute to cataract formation [27].
AG can delay the development of diabetic cataract [26,
28,29], indicating that cataract formation in diabetes involves
glycation.  The  reduced  formation  of  acellular  collapsed
capillary strands by AG suggests a potential role for glycation
in vascular damage [29]. AG can delay cataract development
in UPL rats (a newly developed hereditary cataract model)
possibly by inhibiting the rise in Ca2+ levels [30]. Aspirin
(ASA) and ASA-like analgesics have been studied in a variety
of model systems including diabetic rats [31]. A variety of
laboratory and epidemiological evidence supports the benefits
of  ASA-like  drugs,  but  there  has  been  no  clinical  trial
specifically in patients with cataract [32-34].
However,  none  of  the  clinical  trials  of  other  drug
therapies showed any convincing anti-cataract effect of the
compounds or mixtures tested. Therefore, a successful anti-
cataract drug still remains to be developed. We previously
used the streptozotocin (STZ)-induced cataract model in rats
successfully to assess ASA, paracetamol, ibuprofen [31], N-
acetylcysteine, and glutathione ethyl ester eye drops [35] as
anti-cataract drugs. In this study, we investigate CA, AG, and
ASA as putative anti-cataract drugs in parallel to assess which
can  delay  diabetic  cataract  in  rats.  We  applied  the  drugs
topically as this minimizes the possibility of side effects. The
three eye drops were used for the first time in a streptozotocin-
induced cataract study.
METHODS
Materials:  Streptozotocin,  CA,  AG,  ASA,  and  5-
hydroxymethylfurfural (5-HMF) were purchased from Sigma
Chemical  Co  (Beijing,  China).  Protein  and  enzyme
quantification  kits  were  obtained  from  Jiancheng  Biology
Company (Nanjing, China). Glucotrend 2 was from Roche
Diagnostics Limited Company (Xi’an, China). Test-Tape was
from Zhujiang Biological and Chemical Reagents Company
(Guangzhou, China). All other chemicals and solvents were
of analytical grade and were obtained from local companies.
Animal model: The experiments, which lasted over 14 weeks,
were performed using Sprague-Dawley male rats (Laboratory
Animal Research Centre, Fourth Military Medical University,
Xi’an,  China),  which  were  housed  in  individual
polypropylene breeding cages under a day/night cycle of 12
h  at  room  temperature  (20  °C−25  °C).  Animal  care  and
protocols  were  in  accordance  with  and  approved  by  the
Institutional Animals Ethics Committee and conformed to the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
All the lenses were examined at the slit lamp before the
induction of diabetes, and those with any defect in the lens or
cornea  were  rejected.  The  rats  were  weighed,  and  seven
groups  were  established  with  a  comparable  weight
distribution  (ranging  from  112.0±19.3  g  to  143.0±16.2  g;
p>0.05).
The  rats  in  diabetic  groups  were  injected
intraperitoneally, avoiding the intestine, with streptozotocin
(65 mg/kg bodyweight) dissolved in 20 mM sodium citrate
buffer, pH 4.5 (10 mg streptozotocin per 1 ml citrate buffer).
The streptozotocin solution was sterilized through a 0.22 μm
Millipore filter (Oxford Immunotec Ltd., Oxford, UK) into a
sterilized container kept on ice and used within 10 min of
dissolving. The non-diabetic rats (group I, n=5) were injected
with sterilized buffer alone. After three days, the blood of each
rat  was  tested  for  glucose  with  Glucotrend  2  (Roche
Company, Basel, Switzerland). The urine of each rat was
tested  for  glucose  with  Test-Tape  at  the  same  time.  Any
streptozotocin-injected rats that had no detectable glucose in
the  urine  were  rejected.  Fasting  blood  glucose  was  then
measured in all rats to confirm that the streptozotocin-injected
rats were diabetic (more than 14 mM) and that the control rats
were  not.  In  this  study,  diabetes  was  assessed  by  the
measurement of sugar both in blood and in urine at the same
time. We found that measuring urine sugar is simple, less
expensive, and highly reliable. Although the measurement of
urine sugar is simple, the result is not precise. The blood
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2283glucose  of  rats  varies  in  24  hours.  Therefore,  the  use  of
simultaneous measurement of urine sugar and blood glucose
is the better way compared to measurement of urine sugar or
blood glucose alone.
The diabetic rats (n=59) were then divided randomly into
groups II–VII and received 5 mg/ml CA drops (group II; n=9),
10 mg/ml CA drops (group III; n=9), 0.5 mg/ml ASA drops
(group IV; n=9), 1 mg/ml AG drops (group V; n=9), and 2 mg/
ml AG drops (group VI; n=9), all in 25 mM sodium phosphate
buffer  (pH  7.4).  The  untreated  diabetic  group  constituted
group VII (n=14). The rats were initially given no treatment
until  it  was  certain  that  those  rats  in  groups  II–VII  were
diabetic.  Then,  eye  drops  consisting  of  25  mM  sodium
phosphate buffer (pH 7.4) with the relevant drugs dissolved
in it were administered twice daily to the left eyes of the treated
groups, and the untreated diabetic group (group VII) received
the buffer solution alone. The drug solutions were made fresh
daily. The rats were fed with standard chow ad libitum. Only
22% (14/64) of diabetic rats and none of the controls suffered
unscheduled deaths. The deaths were mostly toward the end
of the experiment.
Monitoring rat corneal staining: To evaluate the safety of eye
drops, the extent of the corneal staining was observed. After
anesthetizing  the  rats  using  ether  vapor,  2%  fluorescein
sodium solution was dropped into the rat eyes, and rat corneal
staining was monitored using a slit lamp (Haag-Streit BQ900,
Koeniz, Switzerland). The slit width was 0.3 mm, and light
angle was 45°. Magnification was 50X. The photographs of
rat corneal staining were taken monthly with a BQ900 slit
lamp  camera  (Haag-Streit  BQ900).  The  extent  of  corneal
staining was graded according to the method described by
Wander et al. [36] with minor modifications: Grade 0, no
staining; grade 1, up to a quarter of the cornea stained; grade
2, a quarter to a half of the cornea stained; grade 3, more than
half of the cornea stained.
Observation of cataract: Progression of cataract formation in
both lenses of all rats was followed by slit lamp observation
using  a  Haag-Streit  BQ  900  model  and  recorded  by
photography.  The  pupils  were  dilated  with  a  drop  of
tropicamide,  and  after  at  least  5  min,  the  rats  were
anaesthetized  by  ether  inhalation.  Grading  of  lens
opacification was performed according to the Oxford system
[31],  and  the  initiation,  progression,  and  maturation  of
lenticular opacity was graded into seven stages as follows:
grade 0, clear; grade 1, clear nucleus with wide sutures; grade
2, slight dense nucleus with opacities radiating from sutures;
grade 3, dense nucleus without clefts; grade 4, dense nucleus
with clefts; grade 5, nuclear cataract with clefts; grade 6,
nuclear cataract with dense radial opacities; grade 7, nuclear
cataract with whole lens opacities (Figure 1). The stage of
cataract was scored according to the classification described
above.
Lens preparation: The rats were sacrificed, and the lenses
were removed for measurement of the level of glutathione
(GSH) and glycated protein and of the activity of glutathione
reductase (GR) and catalase (CAT). The eyes were removed,
and the lenses were dissected out, placed into pre-weighed
Eppendorf tubes, and frozen until they were analyzed. Left
and right lenses were assayed in the same way.
Figure  1.  Progression  of  cataract  in  the  left  lenses  of  untreated
diabetic rats, group VII, assessed at the slit lamp. The grades are as
follows: grade 0, clear; grade 1, clear nuclear with wide sutures;
grade 2, slight dense nuclear with opacities radiating from sutures;
grade 3, dense nuclear without clefts; grade 4, dense nuclear with
clefts; grade 5, nuclear cataract with clefts; grade 6, nuclear cataract
with dense radial opacities; and grade 7, nuclear cataract with whole
lens opacities.
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2284Free, reduced glutathione in the lens: The measurement of
free, reduced GSH was performed using the 5,5′-dithiobis-[2-
nitrobenzoic acid] (DTNB) method [37]. The right and left
lenses  were  defrosted  within  six  days  of  dissection  and
freezing and ground in 1 ml 10% trichloroacetic acid (TCA)
then left for 20 h before centrifugation at 11,500x g at room
temperature for 20 min. The supernatant was removed into a
pre-weighed tube. The precipitate was washed twice with 10%
TCA  and  centrifuged  for  20  min  and  the  supernatants
combined.  The  protein  precipitate  was  retained  for
measurement of the glycated proteins. Two lots of 0.5 ml
supernatant from each tube were made up to 1 ml by adding
10% TCA and 2 ml of 1 M Tris, pH 9.0 followed by 50 μl
DTNB (dissolved in ethanol at a concentration of 3.965 mg/
ml) and mixed well. Standards were made using different
volumes of 0.1 mM reduced GSH in 10% TCA and making
up to 1 ml with 10% TCA. Reaction blanks consisted of 1.0 ml
10% TCA, Tris, and DTNB. The reaction solution duplicates
after shaking when left to stand for 5 min at room temperature,
and the absorbance was read at 412 nm. The concentration of
GSH was read from a standard graph.
Glycation of lens proteins: Determination of glycation of lens
proteins was based on the method described by Blakytny and
Harding [4]. Protein that precipitated during the determination
of GSH in both the right and left lens was suspended in 1 ml
diethyl ether to remove TCA and left for 10 min at room
temperature before centrifugation for 5 min at 11,500x g. The
supernatant was removed and the pellet washed twice more
with diethyl ether (1 ml and 0.5 ml). The pellet was dried in a
fume cupboard to remove any remaining diethyl ether. Then,
upon boiling glycated protein in the presence of a weak acid,
5-hydroxymethylfurfural (5-HMF) was released into solution.
Any solubilized protein was then precipitated out of solution.
Thiobarbituric acid forms an adduct with 5-HMF that absorbs
at 443 nm.
Dried protein pellets (25 mg) were weighed out into twist-
top  vials  to  which  1  ml  of  1  M  oxalic  acid  was  added.
Standards consisted of 5-HMF in 1 ml of 1 M oxalic acid and
the blanks being 1 ml of 1 M oxalic acid alone. The vials were
kept at 100 °C for 2 h and then cooled to room temperature
before removal of 0.15 ml for protein determination. The
remaining  solution  was  transferred  to  centrifuge  tubes  to
which 1 ml of 40% TCA was added and cooled in an ice bath
for 10 min to allow protein precipitation. The tubes were
centrifuged for 15 min at 3,500x g at room temperature, and
2×0.8 ml of the supernatant from each tube was placed in
Eppendorf tubes for further centrifugation at 11,500x g for 5
min at room temperature. The supernatant from each of the
tubes  (0.75  ml)  was  incubated  with  0.25  ml  of  0.05  M
thiobarbituric acid (TBA), adjusted to pH 6.0 with 1 M sodium
hydroxide at 40 °C for 40 min, and then allowed to cool at
room temperature for 15 min. The absorbance was read at 443
nm against a blank, and glycation was determined from a
standard graph using 5-HMF. After boiling in oxalic acid,
0.15 ml was removed (see above) and diluted 100 fold. Then,
two 1 ml aliquots of this diluted protein were used for protein
assay.
Assay of glutathione reductase and catalase activity: Protein
concentration was determined by Lowry's method using a
protein  assay  kit  from  Jiancheng  Company.  Glutathione
reductase (GR) and catalase (CAT) was determined using an
assay kit from Jiancheng Company. GR activity was measured
according  to  the  procedure  in  which  oxidized  glutathione
(GSSG) was reduced to GSH, which was catalyzed by GR
with NADPH as the cofactor. The decrease in the optical
density at 340 nm was recorded at 25 °C for 2 min. The units
of  enzymatic  activity  were  calculated  using  an  extinction
coefficient  of  6.22  mM•cm−1  for  NADPH.  One  unit  was
equivalent to the oxidation of 1 mmol of NADPH per min.
CAT activity in the lens was assayed with hydrogen peroxide
as the substrate through the use of a method based on the direct
measurement of H2O2 decomposition. The final volume of
each enzyme assay was 3 ml of substrate and 20 μl of the
supernatant of lens homogenate. The assay was performed at
25 °C and at 240 nm. Enzyme activity was expressed as units
per gram of protein, and one unit of CAT activity represented
1 mmol H2O2 decomposed per min.
Data  analysis:  Unless  otherwise  stated,  differences  were
assessed using Student’s t test. Analysis of cataract grades in
different rat groups was analyzed on individual lenses using
a Wilcoxon Signed Ranks Test.
RESULTS
Blood glucose after injection of streptozotocin: Rats were
made diabetic with streptozotocin. Diabetes was confirmed
by  measuring  the  level  of  plasma  glucose.  They  were
designated as non-diabetic rats (<14 mmol/l plasma glucose)
and diabetic rats (>14 mmol/l plasma glucose).
About 13.9% (11/79 rats) of the rats responded to the
streptozotocin  injection  (blood  glucose>14  mmol/l)
according to fasting blood glucose, and 74.7% (59/79) of the
rats  responded  to  the  streptozotocin  injection  (blood
glucose>14  mmol/l)  according  to  random  blood  glucose.
Based  on  the  later  data  of  the  experiment,  random  blood
glucose testing was more reliable for distinguishing diabetic
rats from non-diabetic rats. Fifty-nine diabetic rats were then
used throughout experiment. One month after the diabetic rat
model was set, five rats had to be rejected because blood
glucose had fallen below 14 mmol/l (one rat each from Group
II, V, and VII and two rats from Group III).
The  change  of  rat's  weight:  There  was  no  statistically
significant difference in the weight gain among the diabetic
rats (p>0.05; Table 1). The diabetic rats had lower weight gain
compared to the normal rats during the experimental period
(p<0.05). However, treatments of CA, AG, or ASA to diabetic
rats did not normalize bodyweights to a significant extent
(Group II−VI).
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2285Change in blood glucose: The diabetic rats have a higher
blood glucose level compared to the normal rats during the
experimental  period  (Table  2).  There  was  no  statistically
significant difference in the blood glucose levels between the
different  groups  of  diabetic  rats  (p>0.05).  Glucose  levels
remained stable throughout the experiment.
Corneal staining following eye drop use: The extent of corneal
stain was observed throughout the experiment. There was no
TABLE 1. THE BODYWEIGHT OF ALL GROUPS OF RATS DURING THE EXPERIMENTS.
Time
Body weight (g)
Group I Group II Group III Group IV Group V Group VI Group VII
Before
injection
143± 16.17
     (n=5)
120.4±13.57
(n=9)
116±26.7
   (n=9)
112.2±19.9
(n=9)
116±18.48
    (n=9)
119.8±11.95
(n=9)
112.9±18.9
(n=14)
1 wk 234.6±18.13
(n=5)
171.6±19.7
    (n=8)
168.1±36.57
(n=8)
146.8±30.6
(n=9)
167±27.3
    (n=9)
157.4±23.2
    (n=9)
169±22.6
(n=13)
2 wk 283.2±17.46
(n=5)
189.1±27.70
(n=8)
184.6±40.59
(n=7)
164.2±34.2
(n=9)
187±27
  (n=8)
174.9±28.1
    (n=9)
191.6±22.6
(n=13)
4 wk 378.4±13.83
(n=5)
191.4±61.10
(n=8)
196.1±61.38
(n=7)
157.2±55.1
(n=9)
204.9±49.6
    (n=8)
159.9±43.8
    (n=9)
219.8±37.7
(n=13)
5 wk 429±15.39
    (n=5)
222±64.17
    (n=8)
231.7±69.5
    (n=7)
171.1±57.5
(n=9)
224.3±55.4
    (n=8)
183.6±48.3
    (n=9)
227.4±52.2
(n=13)
6 wk 452±15.60
     (n=5)
232.7±66.12
(n=8)
239.6±72.75
(n=7)
176.4±60.8
(n=9)
236.6±62.4
    (n=8)
188.1±50.2
    (n=9)
245.4±52.9
(n=13)
7 wk 488.6±14.28
(n=5)
225.2±77.92
(n=8)
240.8±83.1
    (n=7)
172.9±74.5
(n=9)
235.4±75.3
    (n=8)
171.6±59.6
    (n=9)
238.7±68.7
(n=13)
8 wk 498±22.90
    (n=5)
233.7±87.03
(n=8)
247.4±90.37
(n=7)
173.3±71.9
(n=9)
248.9±71.9
    (n=8)
184.1±66.0
    (n=8)
248.6±73.5
(n=13)
9 wk 532.6±22.31
(n=5)
237.4±109.1
(n=8)
254.8±99.0
    (n=7)
170.7±77.2
(n=9)
247.6±88.6
    (n=7)
181.1±58.3
    (n=7)
236.5±90.8
(n=13)
10 wk 542.8±17.74
(n=5)
233.8±104.2
(n=8)
249±104.3
    (n=7)
183.0±73.9
(n=8)
246.5±93.3
    (n=7)
168.6±60.0
    (n=7)
238.5±86.1
(n=13)
11 wk 558.4±27.79
(n=5)
247.5±105.4
(n=7)
265.3±102.3
(n=6)
173.4±74.6
(n=8)
242.3±100.1
(n=7)
170.2±74.7
    (n=6)
257.6±83.7
(n=10)
12 wk 550±34.46
    (n=5)
244.8±112.7
(n=7)
265.4±114.1
(n=5)
159.9±67.9
(n=8)
252.3±107.9
(n=7)
143.3±54.0
    (n=6)
246.8±89.9
(n=10)
13 wk 550.4±37.70
(n=5)
242.1±117.7
(n=7)
289.3±104.7
(n=5)
167.3±58.8
(n=7)
248.1±105.0
(n=7)
142.6±55.2
    (n=5)
244.5±89.5
(n=10)
The data are the mean±SD. Weights are significantly different between Group I and Group II-VII after STZ injection. There
are no significant differences between the treated diabetic rats (from Group II-VI) and the untreated diabetic rats (Group VII)
two weeks after STZ injection. However, groups IV and VI were significantly lighter than the untreated diabetic rats from week
4 through week 13 (p<0.05). On the eighth week of diabetes, blood glucose of rat number in group V was 13.3 mmol/l (<14
mmol/l), and the rat died. Then, on the eighth week of diabetes, one rat was lost. Finally, five rats were taken out because of
low blood glucose, and 14 rats were lost because of death. One rat is an overlap. The total number of rats studied was then 18.
Group I: Normal; Group II: Carnosine treated (5 mg/ml); Group III: Carnosine treated (10 mg/ml); Group IV: Aspirin treated;
Group V: Aminoguanidine treated (1 mg/ml); Group VI: Aminoguanidine treated (2 mg/ml); and Group VII: Untreated diabetic.
TABLE 2. BODYWEIGHTS OF ALL GROUPS OF RATS DURING THE EXPERIMENTS.
Time
Blood glucose (mmol/l)
Group I Group II Group III Group IV Group V Group VI Group VII
72 h 6.8±0.6 (n=5) 29.2±6.1 (n=9) 30.5±6.3 (n=9) 31.0±2.9 (n=9) 28.0±6.5 (n=9) 32.6±1.0 (n=9) 29.8±4.2 (n=14)
4 wk 5.8±0.3 (n=5) 29.7±8.6 (n=8) 28.2±8.7 (n=7) 31.7±2.5 (n=9) 28.49±7.8 (n=8) 33.0±0.5 (n=9) 27.0±8.1 (n=13)
8 wk 6.2±0.6 (n=5) 29.3±8.4 (n=8) 27.5±11.6 (n=7) 29.2±3.8 (n=9) 27.3±9.3 (n=8) 30.1±2.6 (n=8) 28.2±5.7 (n=13)
12 wk 5.78±1.1 (n=5) 29.2±9.0 (n=7) 25.1±13.1 (n=5) 30.7±3.7 (n=8) 26.7±9.7 (n=7) 30.0±3.4 (n=6) 28.7±6.3 (n=10)
13 wk 5.9±0.9 (n=5) 29.5±9.4 (n=7) 24.8±13.4 (n=5) 32.4±1.6 (n=7) 27.7±10.2 (n=7) 29.6±5.2 (n=5) 28.5±6.8 (n=10)
The data are the mean±SD. Blood glucose levels in all groups of diabetic rats (Group II−VII) were significantly higher than in
the normal rats (Group I). There were no significant differences between the six diabetic groups at any given stage (Group II
−VII). Group I: Normal; Group II: Carnosine treated (5 mg/ml); Group III: Carnosine treated (10 mg/ml); Group IV: Aspirin
treated; Group V: Aminoguanidine treated (1 mg/ml); Group VI: Aminoguanidine treated (2 mg/ml); and Group VII: Untreated
diabetic.
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2286significant staining in the cornea from normal rats. With the
progress  of  diabetes,  fluorescent  staining  on  the  cornea
gradually appeared in diabetic rats. Compared with normal
rats, corneal staining points (median) increased slowly four
weeks after STZ injection (Table 3). Four weeks after STZ
injection there were significant differences between normal
rats  and  all  groups  of  diabetic  rats  (p<0.05),  and  corneal
staining increased with the period of diabetes, indicating the
defect  of  the  cornea  occurred  in  diabetes.  However,  no
significant differences between groups of diabetic rats were
noted at 4, 8, and 12 weeks after STZ injection (p>0.05),
confirming the safety of eye drops used in the current study.
In addition, no corneal opacity was observed in diabetic rats,
but minor corneal ulcers appeared in severely diabetic rats.
Progression of lens opacification: All of the diabetic rats
developed cataracts more or less at the same rate. The lens did
not  progress  to  opacity  until  the  fourth  week  after  STZ
injection (Table 4, Figure 2). Unlike the diabetic rats, the
control rats retained clear lenses throughout. The untreated
diabetic rats seemed to progress to grade 2 cataract faster than
the treated groups (Table 4, Figure 2). After five weeks, all
diabetic groups had reached grade 2. After that, there seemed
to be little difference between the diabetic groups. However,
the progression of cataracts in all treated groups was slightly
delayed  between  the  sixth  week  and  eighth  week.  The
difference between groups was not statistically significant at
this time.
CA  treatment  delayed  the  progression  of  cataracts  in
diabetic rats, and the delay was statistically significant on the
fourth week of diabetes (p<0.05, when compared with the
untreated diabetic rats). However, opacification progressed
after that and the difference was lost after five weeks. AG
seemed to protect for 11−13 weeks, but there were only five
surviving rats in the low aminoguanidine treatment group
during this period. Therefore, this may result from the random
error due to low numbers for analysis. ASA treatment had no
effect on the progression of lens opacities at any time (p>0.05,
when compared with the untreated diabetic rats).
In comparison with the left eyes (treated) and right eyes
(control), there were significant differences in lens opacity
between the left eyes and the right ones on week 6, 9, and 10
of diabetes in groups II and V. The same statistical difference
was also observed on week 10 in group III and week 8 in group
VI. (p<0.05; Table 4, Figure 2), which indicates less opacity
in the treated eyes than the untreated eyes even in the same
rat.
Activity of enzymes: The antioxidant enzymes, catalase (CAT)
and the reducing peptide glutathione (GSH), decreased in
lenses  of  untreated  diabetic  rats  13  weeks  after  the  STZ
injection (Table 5; p<0.05, when compared with the control
Figure 2. Lens opacity of all groups on difference experimental
periods. All of the diabetic rats developed cataracts more or less at
the same rate. The lens progressed rapidly to opacity from the 6th
week to 10th weeks after STZ injection. Values are expressed as
medians. The “+” represents the middle of that median. Median
representation: 0, clear; 1, clear nucleus with wide sutures; 2, slight
dense nucleus with opacities radiating from sutures; 3, dense nucleus
without clefts; 4, dense nucleus with clefts; 5, nuclear cataract with
clefts; 6, nuclear cataract with dense radial opacities; 7, nuclear
cataract with whole lens opacity.
TABLE 3. CORNEAL STAINING OF ALL RATS IN DIFFERENT PERIODS.
Time
Corneal staining
Group I Group II Group III Group IV Group V Group VI Group VII
72 h 0 (n=5) 0 (n=9) 0 (n=9) 0 (n=9) 0 (n=9) 0 (n=9) 0 (n=14)
4 wk 0 (n=5)* 1 (n=8) 0+ (n=7) 1 (n=9) 1 (n=8) 1+ (n=9) 1 (n=13)
8 wk 0 (n=5)* 1+ (n=8) 1 (n=7) 1+ (n=9) 2+ (n=8) 2+ (n=8) 2 (n=13)
12 wk 0 (n=5)* 2+ (n=7) 2 (n=5) 3 (n=8) 3 (n=7) 3 (n=6) 3 (n=10)
Values are expressed as medians. The “+” represents the middle of that median. The extent of corneal staining was graded
according to the quantity of corneal staining: Grade 0: no staining; grade 1: up to a quarter of the cornea stained; grade 2: a
quarter to half of the cornea stained; grade 3: more than half of cornea stained. The asterisk indicates that p<0.05 (Group I
compared with the diabetic rats). There were no significant differences between any of the diabetic rats (Group II−VII) at any
given stage. Group I: Normal; Group II: Carnosine treated (5 mg/ml); Group III: Carnosine treated (10 mg/ml); Group IV:
Aspirin treated; Group V: Aminoguanidine treated (1 mg/ml); Group VI: Aminoguanidine treated (2 mg/ml); and Group VII:
Untreated diabetic.
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2287rats−group I). CA had a statistically significant effect to raise
the activity of CAT (groups II and III). ASA seemed to raise
CAT levels above control (group I), but the differences were
not statistically significant (p>0.05; Table 5). However, AG
seemed to decrease CAT levels below the control (group I),
suggesting that either AG inhibits CAT or it interferes in the
assay.
Glutathione reductase (GR) did not decrease in the lens
of the untreated diabetic rats 13 weeks after injection (Table
5) whereas CA seemed to have raised GR activity (p<0.05,
when  group  I  was  compared  with  group  VII.  The  water-
soluble proteins decreased in the untreated diabetic rats (Table
5). The three treatments did not significantly prevent these
declines.
There were hyperglycemia-dependent increases in the
glycated  protein  (Table  6).  Significant  differences  in  the
glycated  protein  between  the  control  (Group  I)  and  the
diabetic groups (Group II−VII) were noted. The three drops
TABLE 4. LENS OPACITY OF ALL GROUPS AT DIFFERENT EXPERIMENTAL PERIODS.
Time
Lens opacity
Group I Group II Group III Group IV Group V Group VI Group VII
L R L R L R L R L R
4 wk 0 (n=5) 0a 0 (n=8) 0b 0 (n=7) 1 0 (n=9) 0 0 (n=8) 0 0 (n=9) 2 (n=13)
5 wk 0 (n=5) 2 2 (n=8) 2 2 (n=7) 2 2 (n=9) 2 2 (n=8) 2 2 (n=9) 2 (n=13)
6 wk 0 (n=5) 2 3c (n=8) 3 3 (n=7) 2 2 (n=9) 2 3e (n=8) 2 3 (n=9) 2 (n=13)
7 wk 0 (n=5) 3 3 (n=8) 4 4 (n=7) 2 2 (n=9) 3 3 (n=8) 2 4 (n=9) 3 (n=13)
8 wk 0 (n=5) 3 4 (n=8) 4 4 (n=7) 3 4 (n=9) 3 4 (n=8) 2+ 4+f (n=8) 3+ (n=13)
9 wk 0 (n=5) 4 6c (n=8) 5 5 (n=7) 3+ 4 (n=9) 4 5e (n=7) 5 7 (n=7) 4 (n=13)
10 wk 0 (n=5) 5 7c (n=8) 6 7d (n=7) 5 7 (n=8) 6 7e (n=7) 6 7 (n=7) 5+ (n=13)
11 wk 0 (n=5) 6+ 7 (n=7) 6+ 7 (n=6) 7 7 (n=8) 6+ 7 (n=7) 7 7 (n=6) 6 (n=10)
12 wk 0 (n=5) 7 7 (n=7) 7 7 (n=5) 7 7 (n=8) 7 7 (n=7) 7 7 (n=6) 7 (n=10)
13 wk 0 (n=5) 7 7 (n=7) 7 7 (n=5) 7 7 (n=7) 7 7 (n=7) 7 7 (n=5) 7 (n=10)
Values are expressed as medians. The “+” represents the middle of that median. Median representation: 0, clear; 1, clear nucleus
with wide sutures; 2, slight dense nucleus with opacities radiating from sutures; 3, dense nucleus without clefts; 4, dense nucleus
with clefts; 5, nuclear cataract with clefts; 6, nuclear cataract with dense radial opacities; and 7, nuclear cataract with whole lens
opacity. Note: ap=0.014 (group II compared with group VII on the fourth week); bp=0.043 (group III compared with group VII
on the fourth week);  cp<0.05 (the left eyes compared with the right ones in the lens opacity at week 6, 9, and 10 in group II);
dp<0.05 (the left eyes compared with the right ones in the lens opacity at week 10 week in group III);  ep<0.05 (the left eyes
compared with the right ones in the lens opacity at week 6, 9, and 10 in group V); and fp<0.05 (the left eyes compared with the
right ones in the lens opacity on the eighth week in group VI). L: the left eyes, which served as the treated eyes; R: the right
eyes, which served as the control eyes. The number of lens (n) represents equally in both the left and right eyes in each group.
Group I: Normal; Group II: Carnosine treated (5 mg/ml); Group III: Carnosine treated (10 mg/ml); Group IV: Aspirin treated;
Group V: Aminoguanidine treated (1 mg/ml); Group VI: Aminoguanidine treated (2 mg/ml); and Group VII: Untreated diabetic.
TABLE 5. ACTIVITY OF SEVERAL ENZYMES AND THE LEVELS OF PROTEINS IN THE LEFT LENS OF RATS 13 WEEKS AFTER INJECTION.
Time Group I
   (n=5)
Group II
    (n=7)
Group III
     (n=5)
Group IV
(n=7)
Group V
(n=7)
Group VI
     (n=5)
Group VII
     (n=10)
CAT 34.0±21.2 96.6±62.5a 111.0±69.0b 94.9±21.2 22.6±18.2 14.0±15.2 28.7±20.3*
GR 5.2±2.7 7.6±3.9c,e 10.4±3.1d,e 5.6±5.0 5.5±3.6 4.1±3.7 5.5±4.3
GSH 102.7±39 76.3±19.5 41.4±13.8 42.5±22.1 66.3±26.9 75.7±45.2 55.2±32.6**
Lens water-soluble
proteins
4.9±0.4 4.4±0.5f 4.32±0.9f 4.4±0.7f 4.3±0.5f 4.4±0.5f 4.7±0.4**
The data are the mean±SD. CAT (catalase) is expressed as µmol/g lens protein. GSH (glutathione) is expressed as mg/g lens
protein. GR (glutathione reductase) is expressed as µmol/g lens protein. The water-soluble protein is expressed as g/l. An asterisk
indicates that p<0.05 (group I compared with group VII). A double asterisk indicates that p<0.001 (group I compared with group
VII). Note: ap<0. 001 (group II compared with group VII); bp=0.002 (group III compared with group VII); cp=0.003 (group II
compared with group VII);  dp<0.001 (group III compared with group VII);  ep<0.05 (groups II-III compared with group I); fp<0.
001 (group II-VI compared with group I). There were no significant differences in the lens water-soluble proteins in any of the
six diabetic groups (Group II-VII). Group I: Normal; Group II: Carnosine treated (5 mg/ml); Group III: Carnosine treated (10
mg/ml); Group IV: Aspirin treated; Group V: Aminoguanidine treated (1 mg/ml); Group VI: Aminoguanidine treated (2 mg/
ml); and Group VII: Untreated diabetic.
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2288treatments  had  an  effect  in  decreasing  glycated  protein
formation  (groups  II−IV  compared  with  group  VII).  No
differences  between  the  left  eyes  (treated)  and  right  eyes
(control) were observed, suggesting that the eyes drops on one
eye may have effects on the other side through the blood-
ocular barrier.
DISCUSSION
In the present study, three putative anti-cataract drugs, CA,
AG, and ASA, administered as eye drops, were investigated
in parallel to assess which can delay diabetic cataract in rats.
The three types of eye drops were used for the first time in a
streptozotocin-induced  cataract  study  and  showed  an
inhibition of cataract at an early stage. CA eye drops produced
a better inhibitory effect than the other two drugs.
Numerous  laboratory  studies  suggest  that  cA  has
antiglycating,  antioxidant,  and  free-radical  scavenging
activity  [7,11-13].  Its  potential  benefit  against  cataract
formation was reported [14,20,22]. Our data showed that CAT
enzyme activity was significantly decreased in the untreated
diabetic rats (group VII) but less so in the CA-treated diabetic
rats. CA raised CAT and GR levels above the control (group
I), suggesting that the part of the mechanism of the protective
effect of carnosine against diabetic cataract is by protecting
catalase  and  GR,  which  in  turn  generally  protect  against
peroxide and oxidation.
Evidence  from  epidemiological,  in  vitro,  and  animal
studies has accumulated to support the idea that ASA-like
drugs protect against cataract. ASA delivered orally can delay
diabetic  cataract  in  rats  [31],  topical  ASA  can  provide
protection  against  galactosemic  cataract  [38]  and  protect
against dexamethasone-induced cataract in cultured rat lens
[34]. However, there was no significant preventive effect on
diabetic cataract in this study by using ASA drops (Group IV).
This may be due to the severity of the diabetes. More loss of
bodyweight was observed in Group IV, although the blood
glucose in the diabetic groups was all above 30 mmol/l. The
presented  results  indicated  that  the  activity  of  CAT  was
increased similarly in the ASA-treated diabetic rats. However,
there  was  no  statistically  significant  difference  when
compared with the untreated diabetic rats. Thus, ASA at such
dosage did not have enough of an effect in inhibiting oxidation
unless the level of blood glucose was not relatively too high
for ASA against diabetic cataract.
AG  can  inhibit  a  variety  of  diabetic  complications,
including cataract [23,26,28,29]. The current data showed that
there  was  no  significant  prevention  by  AG  eye  drops  on
diabetic  cataract.  Compared  with  the  non-treated  diabetic
group (Group VII), the high dose AG-treated group (Group
VI)  had  greater  bodyweight  loss,  suggesting  the  serious
diabetic  effect  in  this  group.  All  measurements  of  blood
glucose were above 30 mmol/l in these diabetic rats, which
may have decreased the chances of protection. Moreover,
CAT activity was significantly decreased in the AG-treated
diabetic rats when compared with the untreated diabetic rats
(Table 5). This indicates that protection against peroxide may
not contribute to the protective effect of AG against diabetic
cataract, especially at our high levels of hyperglycemia.
Lens opacification is a complex phenomenon. Glycation
is one of the contributory factors in lens opacification in this
animal model. The present results showed that the level of lens
protein  glycation  in  the  untreated  diabetic  rats  was
significantly higher than that in the normal rats. But diabetic
rats treated with CA, ASA, and AG had a lower level of
glycated  protein  compared  to  the  untreated  diabetic  rats,
suggesting that CA, ASA, and AG inhibited the formation of
glycated  protein.  If  glycation  was  the  only  factor,
normalization of glycation levels seen in treated diabetic rats
TABLE 6. LEVELS OF GLYCATED PROTEINS IN THE LEFT AND RIGHT LENS OF RATS 13 WEEKS AFTER INJECTION.
 
Group I
  (n=5)
Group II
(n=7)
Group III
(n=5)
Group IV
(n=7)
Group V
(n=7)
Group VI
(n=5)
Group VII
(n=10)
Glycated
proteins
4.2±0.4 4.0±1.2** 3.4±0.3** 3.7±0.5** 4.5±0.7** 4.1±0.3** 5.4±0.5* L
R 4.2±0.4 4.1±0.5** 3.6±0.6** 3.5±0.3** 4.9±0.8** 4.3±0.5** 5.4±0.5*
The data are the mean±SD. Glycated lens protein is expressed as mmoles HMF/mole protein. An asterisk indicates that p<0.001
when group I is compared with group VII, and a double asterisk indicates that p<0.001 for groups II-VI when compared with
group VII. There were no significant differences between the left and right lens in any of the five treated diabetic groups. L: the
left eyes that served as the treated eyes; R: the right eyes that served as the control eyes. The number of lens (n) represents
equally in both the left and right eyes in each group. Group I: Normal; Group II: Carnosine treated (5 mg/ml); Group III:
Carnosine  treated  (10  mg/ml);  Group  IV:  Aspirin  treated;  Group  V:  Aminoguanidine  treated  (1  mg/ml);  Group  VI:
Aminoguanidine treated (2 mg/ml); and Group VII: Untreated diabetic.
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2289should have decreased lens opacification. However, there was
only a delay in these groups, suggesting that other factors also
play  some  role.  Interestingly,  we  also  observed  that  they
inhibited glycation on the right eyes although applied only to
the  left  eyes.  This  indicates  that  the  drops  may  function
through  blood-ocular  barrier.  The  unique  anatomy  and
physiology of the eye offers many challenges to developing
effective drug delivery systems. Historically, drugs have been
administered to the eye as liquid drops instilled in the cul-de-
sac. The transport of molecules among the eye to the other eye
or vitreous/retina and systemic circulation is restricted by the
blood–retinal barrier [39]. The present observation showed
that  glycation  can  be  inhibited  by  these  small  molecules
through the blood-ocular barrier. However, the function still
remains to be developed.
We conclude that CA, ASA, and AG can inhibit glycation
and thus the formation of AGEs. CA seems to be effective in
delaying the progression of lens opacification in diabetic rats
only during the earlier stages compared with AG and ASA
and may be associated with the protective effect against the
inactivation  of  enzymes  and  the  formation  of  AGEs.
Unfortunately, enzymes and GSH could be measured only
after 13 weeks, the end of the experiment, whereas the benefit
of CA was noted at four weeks. Further study of CA and other
potential  drugs  on  their  biological  features  and  their
mechanisms of delaying the progression of cataractogenesis
may provide a new therapy for preventing cataract.
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